Inventor · disambiguated record
Patrick Hwu
Also filed as: HWU PATRICK
12 granted patents·19 pending applications·350 citations·filing 1995–2023
90Inventor score
Top patents by PatentIndex Score
31 records- 0195US8211422B2Chimeric receptor genes and cells transformed therewithESHHAR ZELIG·Filed 1995·Granted Jul 3, 2012·240 cites·30 claims
- 0288US7723111B2Activated dual specificity lymphocytes and their methods of useUS HEALTH·Filed 2001·Granted May 25, 2010·34 cites·15 claims
- 0383US6734014B1Methods and compositions for transforming dendritic cells and activating T cellsUS HEALTH·Filed 1997·Granted May 11, 2004·54 cites·37 claims
- 0478US9512401B2B and T lymphocyte attenuator marker for use in adoptive T-cell therapyRADVANYI LASZLO·Filed 2011·Granted Dec 6, 2016·12 cites·12 claims
- 0578US7749967B2Peptides of a melanoma antigen and their use in diagnostic, prophylactic, and therapeutic methodsUS HEALTH·Filed 2008·Granted Jul 6, 2010·2 cites·15 claims
- 0673US7378277B2Methods and compositions for transforming dendritic cells and activating T cellsUS HEALTH·Filed 2003·Granted May 27, 2008·3 cites·12 claims
- 0769US7419957B2Peptides of melanoma antigen and their use in diagnostic, prophylactic and therapeutic methodsUS HEALTH·Filed 2002·Granted Sep 2, 2008·4 cites·8 claims
- 0868US2009263365A1Methods and compositions for transforming dendritic cells and activating cellsOF HEALTH AND HUMAN SERVICES O·Filed 2007·Application pending·0 cites
- 0966US10894044B2Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancerUNIV TEXAS·Filed 2016·Granted Jan 19, 2021·1 cites·12 claims
- 1062US2025312449A1Metabolic reprograming of adoptively transferred t cells to potentiate antitumor responseH LEE MOFFITT CANCER CT & RES·Filed 2023·Application pending·0 cites
- 1159US11594135B2Methods of CD40 activation and immune checkpoint blockadeUNIV TEXAS·Filed 2016·Granted Feb 28, 2023·0 cites·12 claims
- 1257US2005063947A1Method for treating cancer in humansFiled 2003·Application pending·0 cites
- 1357US2024009241A1Engineered t cell receptors targeting egfr antigens and methods of useUNIV TEXAS·Filed 2021·Application pending·0 cites
- 1456US2023285558A1Engineered t cells and tumor-infiltrating lymphocytes to increase tumor killingUNIV TEXAS·Filed 2021·Application pending·0 cites
- 1556US2024269281A1Car-t cell therapy for triple negative breast cancerH LEE MOFFITT CANCER CT & RES·Filed 2022·Application pending·0 cites
- 1655US2022409663A1Engineered t cells and tumor-infiltrating lymphocytes to overcome immunosuppression in the tumor microenvironmentUNIV TEXAS·Filed 2020·Application pending·0 cites
- 1753US2021170002A1Slc45a2 peptides for immunotherapyUNIV TEXAS·Filed 2020·Application pending·0 cites
- 1851US8252545B2Peptides of a melanoma antigen and their use in diagnostic, prophylactic, and therapeutic methodsHWU PATRICK·Filed 2010·Granted Aug 28, 2012·0 cites·20 claims
- 1951US2023106973A1Methods for expansion of tumor infiltrating lymphocytes and use thereofUNIV TEXAS·Filed 2021·Application pending·0 cites
- 2050US2021172961A1Methods for identifying rna editing-derived epitopes that elicit immune responses in cancerUNIV TEXAS·Filed 2019·Application pending·0 cites
- 2150US2024009240A1Engineered t cell receptors targeting egfr antigens and methods of useUNIV TEXAS·Filed 2021·Application pending·0 cites
- 2249US2021205293A1Combination of topoisomerase-i inhibitors with immunotherapy in the treatment of cancerUNIV TEXAS·Filed 2020·Application pending·0 cites
- 2349US2012093842A1Chimeric receptor genes and cells transformed therewithESHHAR ZELIG·Filed 2011·Application pending·0 cites
- 2449US2010135958A1Method for treating cancer in humansUS HEALTH·Filed 2010·Application pending·0 cites
- 2548US2010158881A1Activated dual specificity lymphocytes and their methods of useU S A AS REPRESENTED BY THE SE·Filed 2010·Application pending·0 cites
- 2647US2019169262A1Slc45a2 peptides for immunotherapyUNIV TEXAS·Filed 2016·Application pending·0 cites
- 2745US12171803B2Methods of CD40 and toll like receptor immune activationMEMGEN INC·Filed 2018·Granted Dec 24, 2024·0 cites·10 claims
- 2840US2019275133A1Immunotherapeutic tumor treatment methodNEKTAR THERAPEUTICS·Filed 2017·Application pending·0 cites
- 2935US2017363629A1Biomarkers and targets for cancer immunotherapyUNIV TEXAS·Filed 2015·Application pending·0 cites
- 3033US2012309691A1Tumor targeted delivery of immunomodulators by nanopolymersZHOU DAPENG·Filed 2011·Application pending·0 cites
- 3131US11673966B2Monoclonal and humanized antibodies to a cancer glycopeptideNANOCRUISE PHARMACEUTICAL LTD·Filed 2017·Granted Jun 13, 2023·0 cites·13 claims
Join the waitlist — get patent alerts
Get an alert when Patrick Hwu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →